Literature DB >> 10449480

Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.

J Martinez-Picado1, L Sutton, M P De Pasquale, A V Savara, R T D'Aquila.   

Abstract

Better detection of minority human immunodeficiency virus type 1 (HIV-1) populations containing gene mutations may improve the usefulness of antiretroviral resistance testing for clinical management. Molecular cloning of HIV-1 PCR products which might improve minority detection can be slow and difficult, and commercially available recombinant virus assays test drug susceptibility of virus pools. We describe novel plasmids and simple methods for rapid cloning of HIV-1 PCR products from patient specimens and their application to generate infectious recombinant virus clones for virus phenotyping and genotyping. Eight plasmids with differing deletions of sequences encoding HIV-1 protease, reverse transcriptase, or Gag p7/p1 and Gag p1/p6 cleavage sites were constructed for cloning HIV-1 PCR products. A simple HIV-1 sequence-specific uracil deglycosylase-mediated cloning method with the vectors and primers designed here was more rapid than standard ligase-mediated cloning. Pooled and molecularly cloned infectious recombinant viruses were generated with these vectors. Replicative viral fitness and drug susceptibility phenotypes of cloned infectious viruses containing patient specimen-derived sequences were measured. Clonal resistance genotyping analyses were also performed from virus isolates, plasma HIV-1 RNA, and infected cell DNA. Sequencing of a limited number of molecular clones detected minorities of resistant virus not identified in the pooled population PCR product sequence and linkage of minority mutations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449480      PMCID: PMC85420     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Uracil DNA glycosylase-mediated cloning of polymerase chain reaction-amplified DNA: application to genomic and cDNA cloning.

Authors:  A Rashtchian; G W Buchman; D M Schuster; M S Berninger
Journal:  Anal Biochem       Date:  1992-10       Impact factor: 3.365

2.  Instability of HIV sequences in high copy number plasmids.

Authors:  K W Peden
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

3.  Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy.

Authors:  K H Mayer; S Boswell; R Goldstein; W Lo; C Xu; L Tucker; M P DePasquale; R D'Aquila; D J Anderson
Journal:  Clin Infect Dis       Date:  1999-06       Impact factor: 9.079

4.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

5.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

6.  A novel method for site-directed mutagenesis using PCR and uracil DNA glycosylase.

Authors:  A Rashtchian; C G Thornton; G Heidecker
Journal:  PCR Methods Appl       Date:  1992-11

7.  Rapid and sensitive viral culture method for human immunodeficiency virus type 1.

Authors:  J B Jackson; R W Coombs; K Sannerud; F S Rhame; H H Balfour
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

8.  Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.

Authors:  T Shirasaka; R Yarchoan; M C O'Brien; R N Husson; B D Anderson; E Kojima; T Shimada; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

9.  Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.

Authors:  T Haertle; C J Carrera; D B Wasson; L C Sowers; D D Richman; D A Carson
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

10.  Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Authors:  A J Japour; D L Mayers; V A Johnson; D R Kuritzkes; L A Beckett; J M Arduino; J Lane; R J Black; P S Reichelderfer; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  14 in total

1.  Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G J Hanna; V A Johnson; D R Kuritzkes; D D Richman; J Martinez-Picado; L Sutton; J D Hazelwood; R T D'Aquila
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.

Authors:  S García-Bujalance; C Ladrón de Guevara; J González-García; J R Arribas; A Gutiérrez
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.

Authors:  S La Seta Catamancio; M P De Pasquale; P Citterio; S Kurtagic; M Galli; S Rusconi
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.

Authors:  M A Martínez; M Cabana; M Parera; A Gutierrez; J A Esté; B Clotet
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

6.  Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.

Authors:  L T Bacheler; E D Anton; P Kudish; D Baker; J Bunville; K Krakowski; L Bolling; M Aujay; X V Wang; D Ellis; M F Becker; A L Lasut; H J George; D R Spalding; G Hollis; K Abremski
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.

Authors:  Maria C Puertas; Maria J Buzón; Mònica Ballestero; Peter Van Den Eede; Bonaventura Clotet; Julia G Prado; Javier Martinez-Picado
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

8.  Epistasis and entrenchment of drug resistance in HIV-1 subtype B.

Authors:  Avik Biswas; Allan Haldane; Eddy Arnold; Ronald M Levy
Journal:  Elife       Date:  2019-10-08       Impact factor: 8.140

9.  Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification.

Authors:  Javier Martinez-Picado; Kristina Morales-Lopetegi; Cristina Villena; Carolina Gutiérrez; Nuria Izquierdo; Silvia Marfil; Bonaventura Clotet; Lidia Ruiz
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

10.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.